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The influence of diabetes on regulatory mechanisms and specific receptors implicated in the contractile response of isolated rabbit carotid
arteries to endothelin-1 was examined. Endothelin-1 induced a concentration-dependent contraction that was greater in arteries from diabetic
rabbits than in arteries from control rabbits. Endothelium removal or NG-nitro-L-arginine enhanced contractions in response to endothelin-1
only in control arteries, without modifying the endothelin-1 response in diabetic arteries. Indomethacin, furegrelate (thromboxane A2
inhibitor), or cyclo-(D-Asp-Pro-D-Val-Leu-D-Trp) (BQ-123; endothelin ETA receptor antagonist) inhibited the contractions in response to
endothelin-1, the inhibition being greater in diabetic arteries than in control arteries. 2,6-Dimethylpiperidinecarbonyl-g-methyl-Leu-Nin-
(methoxycarbonyl)-D-Trp-D-Nle (BQ-788; endothelin ETB receptor antagonist) enhanced the contraction elicited by endothelin-1 in control
arteries and displaced to the right the contractile curve for endothelin-1 in diabetic arteries. In summary, diabetes induces hyperreactivity of
the rabbit carotid artery to endothelin-1 by a mechanism that at least includes: (1) enhanced activity of muscular endothelin ETA receptors; (2)
impairment of endothelin ETB receptor-mediated nitric oxide (NO) release; and (3) enhancement of the production of thromboxane A2.
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Epidemiologic and pathologic data indicate that diabetes
mellitus is a risk factor for ischemic stroke. The prevalence
of cerebrovascular disease, the severity of ischemia, and the
mortality of stroke are higher in diabetic patients than in
nondiabetics patients (Caplan, 1996; Lukovits et al., 1999).
Carotid artery occlusive disease is directly linked to 20–
30% of strokes that occur each year in the United States
(Eugene et al., 1999). The Epidemiology of Diabetes
Interventions and Complications (EDIC) (1999) research
group has reported that in patients with type I diabetes,
intimal–medial thickness is increased in the common and
internal carotid arteries. Moreover, these carotid morpho-0014-2999/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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angiopathy and to risk factors for atherosclerosis, such as
enhanced blood pressure and raised urinary concentrations
of albumin, endothelin-1, and free cortisol (Peppa-Patrikiou
et al., 1998).
The endothelium has a decisive role in regulating both
the tone and the growth of the vessel wall by maintaining a
critical balance between different constrictor (endothelin-1,
angiotensin II, thromboxane A2, and prostaglandin H2) and
relaxant [nitric oxide (NO), prostacyclin, and endothelium-
derived hyperpolarizing factor] substances. Accordingly, the
vasoconstrictor and mitogenic actions of endothelin-1 are
opposed to those of vasodilator and antigrowth factors such
as NO and prostacyclin secreted by endothelial cells.
Diabetes alters the responsiveness of different vascular beds
to several vasoconstrictors and vasodilators, and it has been
hypothesised that endothelial dysfunction could partially
explain many of these altered responses (Haller, 1997; De
S. Llore´ns et al. / European Journal of Pharmacology 486 (2004) 43–5144Vriese et al., 2000). In patients with diabetes mellitus, the
ratio of vasodilating to vasoconstricting substances in the
vessel wall is markedly shifted towards those with a vaso-
constricting action (Haller, 1997; De Vriese et al., 2000).
Since the discovery of endothelin-1 as the most potent
vasoconstrictor and pressor substance (Yanagisawa et al.,
1998), several events have suggested its implication in
various cardiovascular disorders, including those related to
diabetes mellitus. It is clear that many of the well-known
metabolic abnormalities encountered in diabetes mellitus,
such as those affecting plasma insulin, glucose, and lipid
levels, contribute individually and synergistically to alter-
ations in the release and action of endothelin-1 (Hopfner and
Gopalakrishnan, 1999). The endothelin system is altered in
both vascular and neuronal components of the retina in early
diabetic retinopathy (De Juan et al., 2000). The increased
plasma levels of endothelin-1 in diabetic patients (Sarman et
al., 2000; Seligman et al., 2000; Schneider et al., 2002),
together with increased free radical levels and a deficiency
of prostacyclin, have been related to carotid atherosclerosis
in diabetic patients (Kalogeropoulou et al., 2002). Finally,
current experimental evidence suggests that endothelin
antagonism may potentially represent an adjuvant therapeu-
tic tool in the treatment of chronic diabetic complications
(Chakrabarti et al., 2000; Mather et al., 2002).
We have previously reported that cerebral arteries exhibit
hyperreactivity to endothelin-1 after subarachnoid hæmor-
rhage via a mechanism that involves the absence of the
modulatory role of endothelial NO (Alabadı´ et al., 1997). In
two recent studies, we have reported that diabetes changes
endothelial modulatory mechanisms in the rabbit carotid
artery (Miranda et al., 2000a,b). The aim of the present
study was to analyse diabetes-induced changes in the
reactivity of the rabbit carotid artery to endothelin-1, in-
cluding the study of the specific receptors and the effects of
the disease on the endothelial mechanisms that regulate this
response.Table 1
Body weight and glycaemia in control and diabetic rabbits
Body weight (kg) Glycaemia (mmol/l) n
Control rabbits
Initial time 2.53F 0.08 5.8F 0.2 21
6 weeks after 3.49F 0.07 5.9F 0.2 21
Diabetic rabbits
Initial time 2.50F 0.08 5.9F 0.2 22
6 weeks after 2.98F 0.09* 20.4F 0.6* 22
Results are meanF S.E.M.
*Significantly different from corresponding value in control rabbits
( P < 0.01).2. Materials and methods
Forty-three male New Zealand white rabbits were used in
the present study. Animals were randomly divided into two
experimental groups: 21 in the control group and 22
destined for induction of experimental diabetes. Housing
conditions and experimental procedures were in accordance
with the European Union regulations on the use of animals
for scientific purposes (86/609/EEC, Article 5, Appendix II)
and as promulgated by Spanish legislation on March 14,
1988 (RD 223/1988).
2.1. Induction of diabetes and control animals
For induction of experimental diabetes, rabbits weighing
2.0–3.2 kg were sedated with intramuscular injection of
ketamine (40 mg; KetolarR). Diabetes was induced byinjecting alloxan (100 mg kg 1) into the lateral ear vein.
To prevent hypoglycaemia, 10 ml of glucose 5% was
injected intravenously after alloxan, and drinking water
was supplemented with 10% glucose for the first 24 h after
the alloxan injection. Thereafter, the animals were main-
tained on tap water and regular food ad libitum for 6 weeks.
A second group of rabbits (2.1–3.0 kg) was maintained
under the same conditions for the same time period to serve
as age-matched controls (henceforth, ‘‘control rabbits’’).
Diabetic rabbits showed a marked increase in serum glucose
and a failure to increase their body weight when compared
with control rabbits. Table 1 shows the mean values of body
weight and glycæmia before and 6 weeks after diabetes
induction for the rabbits in the diabetic group and for the
rabbits in the control group.
2.2. Isometric tension recording
Six weeks after diabetes induction, the diabetic and the
age-matched control rabbits were anaesthesised with sodium
thiopental (sodium pentothal, 2%, i.v.) and killed by injec-
tion of potassium chloride (10 mEq, 0.5 ml kg 1, i.v.). The
common carotid arteries were dissected free and cut into
cylindrical segments measuring 4 mm in length. Each
segment was prepared for isometric tension recording in
an organ bath. Two stainless steel L-shaped pins (diameter,
125 Am) were introduced through the arterial lumen. One
pin was fixed to the organ bath wall and the other pin was
connected to a strain gauge for isometric tension recording
(isometric tension transducer models Panlab UF-1 and
Letica TRI 201). The organ bath contained 5 ml of Ring-
er–Locke solution that was bubbled continuously with 95%
O2 and 5% CO2 to provide a pH of 7.3–7.4. Temperature
was kept at 37 jC. A resting tension of 2 g was applied to
the arterial segments, and they were allowed to equilibrate
for a period of 60–90 min before the experiments were
started. Tension was readjusted when necessary and the bath
fluid was changed every 15 min. After this period of
equilibration, the reactivity of the arterial segments was
checked by depolarisation with 50 mM KCl. There were not
significant differences in the response to KCl between
arteries from control and diabetic rabbits.
Fig. 1. Concentration–contraction response curves for endothelin-1 in
carotid arteries isolated from control and diabetic rabbits. Values represent
meanF S.E.M. *Significantly different from corresponding value in control
rabbit, P< 0.05.
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The experiments were carried out with carotid arteries
from both control and diabetic rabbits. Concentration–
response curves for endothelin-1 (10 12–3 10 8 M)
were obtained by its cumulative addition to the organ bath.
To assess the influence of the endothelium on the effect of
endothelin-1, concentration–response curves were obtained
with arteries from which the endothelium had been removed
by rubbing the intimal surface with a scored stainless steel
rod (rubbed arteries). The absence of endothelium was
checked either by silver staining or by testing the absence
of a relaxant response to acetylcholine. To assess the
participation of NO in the response of carotid artery to
endothelin-1, concentration–response curves for this pep-
tide were obtained after incubation (20 min) of the carotid
arteries with the inhibitor of nitric oxide synthase (NOS),
NG-nitro-L-arginine (L-NOARG; 10 4 M). To examine the
possibility that an arachidonic acid derivative could modu-
late the arterial response to endothelin-1, we obtained
concentration–response curves for endothelin-1 after incu-
bation (20 min) of the arterial segments with either indo-
methacin (10 5 M), an inhibitor of cyclooxygenase, or
furegrelate (10 5 M), an inhibitor of thromboxane A2
synthesis. In addition, we also obtained concentration–
response curves for endothelin-1 in the presence of both
L-NOARG (10 4 M) and indomethacin (10 5 M). To verify
the endothelial origin of the arachidonic acid derivative,
concentration–response curves for endothelin-1 after incu-
bation with indomethacin (10 5 M) were obtained for
rubbed arteries. To examine the participation of specific
endothelin ETA receptors, concentration–response curves
for endothelin-1 were obtained in the presence of the
selective endothelin ETA receptor antagonist, cyclo-(D-
Asp-Pro-D-Val-Leu-D-Trp) (BQ-123; 10 6 M). Finally, to
examine the participation of specific ETB receptors, con-
centration–response curves for endothelin-1 were obtained,
in unrubbed and rubbed arteries, in the presence of the
selective endothelin ETB receptor antagonist, 2,6-dimethyl-
piperidinecarbonyl-g-methyl-Leu-Nin-(methoxycarbonyl)-D-
Trp-D-Nle (BQ-788; 10 6 M).
2.4. Drugs and solutions
Alloxan, endothelin-1, indomethacin, furegrelate, BQ-
123, and BQ-788 were obtained from Sigma and L-NOARG
was from Peptide Institute. Alloxan was dissolved in saline
solution. Endothelin-1 was dissolved in 0.1% aqueous acetic
acid and diluted in a mixture of phosphate-buffered saline
solution (150 mM NaCl + 10 mM NaH2PO4) and 0.05%
bovine serum albumin. Furegrelate, BQ-123, BQ-788 (so-
dium salt), and L-NOARG were dissolved in twice-distilled
water; the L-NOARG solution required sonication. Indo-
methacin was dissolved in ethanol and diluted in saline
solution. The composition of the Ringer–Locke solution is
as follows (in mM): NaCl, 120; KCl, 5.4; CaCl2, 2.2;MgCl2, 1.0; NaHCO3, 25; and glucose, 5.6. To prepare
the KCl-depolarising solution, NaCl was replaced by an
equimolar amount of KCl in the normal Ringer–Locke
solution.
2.5. Statistical analysis
Comparisons of body weight and glycæmia between
control and diabetic rabbits were made by using unpaired
Student’s t test. Endothelin-1-induced contractions are
expressed as a percentage of the previous depolarisation
induced by 50 mM KCl. For each concentration–response
curve, the maximum effect (Emax) and the concentration of
endothelin-1 that produced half of Emax (EC50) were calcu-
lated. Maximum effects are expressed as meanF S.E.M.
and EC50 as the geometric mean with its confidence limits
(95%) for repeated experiments. Statistical comparisons of
Emax and  log EC50 (pD2) values between arteries from
control and diabetic rabbits receiving the same experimental
treatment were made by using unpaired Student’s t test.
Comparisons between the values of Emax and pD2 of the
concentration–response curves for endothelin-1 obtained
with the different treatments in the arteries from the control
rabbits were made using analysis of variance (ANOVA)
followed by the Newman–Keuls test. The same tests were
used to compare the Emax and pD2 values of the response
curves for the different treatments in the arteries from
diabetic rabbits. A probability value of less than 5% was
considered significant.3. Results
Endothelin-1 (10 12–3 10 8 M) induced a concentra-
tion-dependent contraction of the carotid artery from either
control or diabetic rabbits (Fig. 1). The Emax of the concen-
Table 2
Maximum effect (Emax) and EC50 values for concentration– response curves for ET-1 in rabbit carotid artery
Control rabbit Diabetic rabbit
Emax EC50 (M) n Emax EC50 (M) n
Control 108F 4 6.5 (5.4–7.8) 10 10 32 121F 4* 8.7 (7.2–10.5) 10 10 34
Rubbed 124F 6** 9.3 (7.9–11.0) 10 10 21 137F 8 8.3 (6.8–12.6) 10 10 30
L-NOARG (10 4 M) 133F 5** 9.5 (7.9–11.5) 10 10 18 123F 4 1.2 (1.0–1.4) 10 9 23
Indomethacin (10 5 M) 89F 4**,*** 2.9 (2.4–3.4) 10 9**,*** 13 88F 5**,*** 5.7 (5.0–6.8) 10 9*,**,*** 18
L-NOARG (10 4 M)+ indomethacin (10 5 M) 105F 5 1.7 (1.4–2.1) 10 9** 14 114F 3 1.9 (1.7–2.2) 10 9**,*** 16
Rubbed indomethacin (10 5 M) 113F 6 8.3 (6.0–11.5) 10 10 15 126F 14 6.8 (5.7–7.9) 10 10 14
Furegrelate (10 5 M) 81F 5**,*** 8.7 (7.8–8.9) 10 10 12 85F 4**,*** 1.3 (1.2–1.4) 10 9* 16
BQ-123 (10 6 M) 104F 7 7.2 (6.6–7.9) 10 9** 15 97F 3** 6.8 (6.3–7.2) 10 9** 12
BQ-788 10 6 M 133F 7** 8.5 (6.8–10.7) 10 10 15 129F 5 1.8 (1.4–2.2) 10 9*,** 10
Rubbed BQ-788 (10 6 M) 128F 4** 2.7 (2.3–3.1) 10 9**,*** 14 143F 6* 2.9 (2.7–3.1) 10 9**,*** 14
Emax values are expressed as a percentage of depolarisation obtained with 50 mM KCl. Emax values are meanF S.E.M. and EC50 values are means and
confidence limits.
n= number of arterial segments.
*Significantly different from corresponding value in control rabbits ( P< 0.05).
**Significantly different from corresponding control value ( P < 0.05).
***Significantly different from corresponding rubbed value ( P< 0.05).
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from diabetic rabbits than in arteries from control rabbits,
without there being significant differences between EC50
values (Table 2). In arteries from control rabbits, mechanical
removal of the endothelium significantly increased the
maximal contraction induced by endothelin-1 without sig-
nificantly changing the EC50 value (Fig. 2, Table 2). In
arteries from diabetic rabbits, removal of the endothelium
did not significantly affect the endothelin-1-induced con-
traction both in terms of Emax and EC50 values (Fig. 3, Table
2). The concentration– response curve for endothelin-1
obtained in rubbed arteries from diabetic rabbits did not
show significant differences in EC50 and Emax values withFig. 2. Concentration–contraction response curves for endothelin-1 in
carotid arteries isolated from control rabbits: control, without endothelium
(rubbed), incubated with L-NOARG (10 4 M), incubated with indometh-
acin (10 5 M), incubated with L-NOARG (10 4 M) plus indomethacin
(10 5 M), rubbed incubated with indomethacin (10 5 M), and incubated
with furegrelate (10 5 M). Values represent meanF S.E.M.respect to values obtained for rubbed arteries from control
rabbits (Table 2).
Incubation with L-NOARG (10 4 M) significantly en-
hanced the maximal contraction induced by endothelin-1 in
arterial segments from control rabbits (Fig. 2, Table 2). In
arterial segments from diabetic rabbits, L-NOARG treatment
did not significantly modify the contractile response to
endothelin-1 (Fig. 3, Table 2). There were no significant
differences between concentration– response curves for
endothelin-1 in L-NOARG-treated arteries from control
rabbits and those from diabetic rabbits (Table 2).
The incubation of carotid arteries from control (Fig. 2) or
diabetic (Fig. 3) rabbits with indomethacin (10 5 M)Fig. 3. Concentration–contraction response curves for endothelin-1 in
carotid arteries isolated from diabetic rabbits: control, without endothelium
(rubbed), incubated with L-NOARG (10 4 M), incubated with indometh-
acin (10 5 M), incubated with L-NOARG (10 4 M) plus indomethacin
(10 5 M), rubbed incubated with indomethacin (10 5 M) and incubated
with furegrelate (10 5 M). Values represent meanF S.E.M.
Fig. 5. Concentration–contraction response curves for endothelin-1 in
carotid arteries isolated from diabetic rabbits: control, without endothelium
(rubbed), incubated with BQ-123 (10 6 M), incubated with BQ-788
(10 6 M), and rubbed incubated with BQ-788 (10 6 M). Values represent
meanF S.E.M.
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EC50 (displaced to the right) of the concentration–response
curve to endothelin-1 (Table 2). The EC50 of the concen-
tration–response curve for endothelin-1 obtained in indo-
methacin-treated arteries from diabetic rabbits was
significantly higher than that obtained in indomethacin-
treated arteries from control rabbits (Table 2).
The incubation of carotid arteries either from control
(Fig. 2) or diabetic (Fig. 3) rabbits with both L-NOARG
(10 4 M) and indomethacin (10 5 M) together significantly
increased the EC50 (displaced to the right) of the concen-
tration–response curve for endothelin-1, without modifying
the Emax value (Table 2).
The incubation of rubbed carotid arteries either from
control (Fig. 2) or diabetic (Fig. 3) rabbits with indometh-
acin (10 5 M) did not significantly modify the concentra-
tion–response curve for endothelin-1 with respect to the
corresponding curve obtained in rubbed arteries in the
absence of indomethacin (Table 2).
The incubation of carotid arteries from control (Fig. 2) or
diabetic (Fig. 3) rabbits with furegrelate (10 5 M) signifi-
cantly inhibited the Emax value of the concentration–re-
sponse curve for endothelin-1, without significantly
modifying the EC50 value (Table 2). The EC50 of the
concentration–response curve for endothelin-1 obtained in
furegrelate-treated arteries from diabetic rabbits was signif-
icantly higher than that obtained in furegrelate-treated
arteries from control rabbits (Table 2).
The incubation of carotid arteries from control rabbits with
BQ-123 (10 6 M) significantly increased the EC50 (dis-
placed to the right) of the concentration–response curve for
endothelin-1, without modifying the Emax value (Fig. 4, Table
2). In arteries from diabetic rabbits, incubation with BQ-123
(10 6 M) inhibited the contractile response to endothelin-1,
both in terms of EC50 and Emax (Fig. 5, Table 2).Fig. 4. Concentration–contraction response curves for endothelin-1 in
carotid arteries isolated from control rabbits: control, without endothelium
(rubbed), incubated with BQ-123 (10 6 M), incubated with BQ-788 (10 6
M), and rubbed incubated with BQ-788 (10 6 M). Values represent
meanF S.E.M.The incubation of carotid arteries from control rabbits
with BQ-788 (10 6 M) significantly increased the Emax
value of the concentration–response curve for endothelin-1,
without modifying the EC50 (Fig. 4, Table 2). In arteries
from diabetic rabbits, incubation with BQ-788 (10 6 M)
significantly increased the EC50 (displaced to the right) of
the concentration–response curve for endothelin-1, without
modifying the Emax value (Fig. 5, Table 2). The EC50 of the
concentration–response curve for endothelin-1 obtained in
BQ-788-treated arteries from diabetic rabbits was signifi-
cantly higher than that obtained in BQ-788-treated arteries
from control rabbits (Table 2).
The incubation of rubbed carotid arteries from either
control (Fig. 4) or diabetic (Fig. 5) rabbits with BQ-788
(10 6 M) significantly increased the EC50 (displaced to the
right) of the concentration–response curve for endothelin-1
with respect to the corresponding curve obtained in rubbed
arteries in the absence of BQ-788 (Table 2). The Emax of the
concentration–response curve for endothelin-1 obtained in
BQ-788-treated rubbed arteries from diabetic rabbits was
significantly higher than that obtained in BQ-788-treated
rubbed arteries from control rabbits (Table 2).
Table 2 summarises the Emax and EC50 values of con-
centration–response curves for endothelin-1 under the dif-
ferent experimental conditions.4. Discussion
The present results demonstrate that experimental diabe-
tes enhances the contractile response of isolated rabbit
carotid artery to endothelin-1. In diabetic rats, an increased
contractile response to endothelin-1 was observed in renal
and mesenteric arteries (Kiff et al., 1991) and aorta (Hopfner
et al., 1999). The activity of endogenous endothelin-1 in the
regulation of the vascular tone of resistance vessels of
patients with type II diabetes mellitus is enhanced (Cardillo
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response to exogenous endothelin-1 (Cardillo et al., 2002).
The vascular hyperreactivity to endothelin-1, together with
the increased plasma levels of this peptide in diabetic
individuals (Sarman et al., 2000; Seligman et al., 2000;
Kalogeropoulou et al., 2002; Schneider et al., 2002), could
play a role in the pathogenesis of cerebral ischæmia in
diabetic patients. The absence of changes in the maximal
contraction of the carotid artery from diabetic rabbits in
response to depolarising solutions (50 mM KCl) and 5-HT
(Miranda et al., 2000b) shows the selectivity of the altered
response to endothelin-1 reported in the present study.
The endothelium has a decisive role in regulating the
contractility of the vessel wall by secreting vasoactive
substances. In the present work, endothelium denudation
of arterial rings from control rabbits enhanced the contrac-
tile response of carotid artery to endothelin-1, indicating that
the endothelium partially counteracts the endothelin-1-me-
diated vasoconstriction. The endothelial modulation of the
vascular contraction in response to endothelin-1 has been
reported in mesenteric arteries (Randall et al., 1989), aorta
(Sakata et al., 1989), and cerebral (Kauser et al., 1990;
Alabadı´ et al., 1997) arteries. In carotid arteries from
diabetic rabbits, endothelium denudation did not significant-
ly modify the contractile action of endothelin-1. This result
would indicate that diabetes impairs the modulatory activity
of the endothelium, and that this alteration could contribute,
at least partially, to the hyperreactivity of the carotid artery
to endothelin-1 observed in diabetic animals. Impairment of
the modulatory activity of the endothelium on the vascular
response to several stimuli has been reported in the aorta
(Pagano et al., 1998) and renal (Costa e Forti and Fonteles,
1998) arteries of alloxan-induced diabetic rabbits and carot-
id arteries and aorta of women with gestational diabetes (Hu
et al., 1998).
We studied the possibility that the modulatory action of
the endothelium could be achieved, at least partially,
through the release of NO. NO is synthesised from the
amino acid, L-arginine, by the Ca2 +-dependent enzyme,
NOS. There are three isoenzymes of NOS (Moncada et
al., 1997): two constitutive isoforms [endothelial nitric
oxide synthase (eNOS) and neuronal nitric oxide synthase
(nNOS)] and one inducible isoform [inducible nitric oxide
synthase (iNOS)]. Incubation of carotid arteries from control
rabbits with the inhibitor of the constitutive NOS, L-
NOARG, significantly enhanced the contractile response
of arterial segments to endothelin-1, thus indicating the
participation of NO in the modulatory action of the endo-
thelium on this response. This result is similar to that
obtained previously in goat middle cerebral artery (Alabadı´
et al., 1997). In addition, in vivo studies have demonstrated
that endothelin-1 stimulates the release of NO in the human
forearm circulation (Cardillo et al., 2000). In arteries from
diabetic rabbits, L-NOARG did not significantly enhance the
contraction induced by endothelin-1. This result suggests
that diabetes impairs the modulatory action of endothelialNO on the response of the carotid artery to endothelin-1.
Results previously obtained in our laboratory show that
experimental diabetes enhances the modulatory activity of
endothelial constitutive NO on the response of the rabbit
carotid artery to 5-hydroxytryptamine (Miranda et al.,
2000b). Therefore, the impairment of the modulatory action
of endothelial NO on the response of the carotid artery from
diabetic rabbits to endothelin-1 cannot be explained by an
unspecific defect in the activity of the eNOS, but by a
specific response to the contractile agonist.
In the present work, we also examined the participation
of an arachidonic acid metabolite derived via cyclooxyge-
nase in the modulation of the response of the carotid artery
to endothelin-1. The results obtained show that indometh-
acin, an inhibitor of the enzyme cyclooxygenase, signifi-
cantly decreased the sensitivity of the carotid artery to
endothelin-1. This result suggests the participation of a
vasoconstrictor prostanoid mediating the contractile action
of endothelin-1 in the carotid artery. Because furegrelate, an
inhibitor of thromboxane A2 synthesis, inhibited the con-
tractile response to endothelin-1, it can be assumed that this
vasoconstrictor prostanoid is thromboxane A2. To ascertain
the endothelial origin of this prostanoid, concentration–
response curves for endothelin-1 were obtained in rubbed
arteries in the presence of indomethacin. Our results show
that the response of rubbed arteries preincubated with
indomethacin to endothelin-1 was not significantly different
from that obtained in the absence of the inhibitor, thus
indicating the endothelial origin of the vasoconstrictor
prostanoid. Endothelin-1 stimulates the production of pros-
taglandins and thromboxane A2 from the metabolism of
arachidonic acid via cyclooxygenase (Takayasu et al.,
1989). Endothelial thromboxane A2 modulates the response
to endothelin-1 of dog basilar artery (Shirahase et al., 1991),
rat hepatic vascular bed (Kurihara et al., 1992), and aorta
from hypertensive rats (Taddei and Vanhoutte, 1993). Re-
cently, we have reported that the endothelium modulates the
response of the rabbit carotid artery to acetylcholine (Mi-
randa et al., 2000a) and 5-hydroxytryptamine (Miranda et
al., 2000b) and that of the rabbit renal artery to 5-hydroxy-
tryptamine (Miranda et al., 2002) by releasing both NO and
a vasoconstrictor prostanoid. Because in both indomethacin-
and furegrelate-treated arteries from diabetic rabbits the
EC50 values were increased with respect to those obtained
in the corresponding arteries from control rabbits, it can be
deduced that indomethacin and furegrelate were more
effective at inhibiting responses in diabetic than in control
arteries. This result indicates a greater modulatory role of
thromboxane A2 in the diabetic state, which could partially
contribute to the hyperreactivity of the rabbit carotid artery
to endothelin-1 in diabetes. The renal production of throm-
boxane A2 and prostacyclin is increased in diabetic rats
(Okumura et al., 2000). In contrast, other studies show a
decreased formation of vasoconstrictor prostanoid in rat
mesenteric arterial bed in response to methoxamine (Makino
and Kamata, 1998), rabbit carotid arteries in response to
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mine (Miranda et al., 2000b), and rabbit renal arteries in
response to 5-hydroxytryptamine (Miranda et al., 2002) in
diabetes. These data support the specificity of the changes in
modulatory mechanisms of the arterial response to endothe-
lin-1 mentioned above, and show that changes in vascular
reactivity induced by diabetes may vary depending on the
species, vascular bed, and stimuli studied. A recent study
reports the existence of sex and regional differences in the
alterations induced by diabetes on the reactivity of vascular
smooth muscles (Sanz et al., 2003).
The vascular actions of endothelin-1 are primarily me-
diated by two distinct G-protein-coupled receptor subtypes
designated as endothelin ETA and ETB (Hopfner and
Gopalakrishnan, 1999). Both endothelin ETA and endothe-
lin ETB receptors are located in smooth muscle cells and
mediate vasoconstriction. Endothelin ETB receptors are also
located in the endothelium and mediate vasodilation
through the activation of the release of NO. In the present
work, the antagonist of endothelin ETA receptors, BQ-123,
significantly inhibited the contractile response of the carotid
artery to endothelin-1, both in control (increased the EC50
value, without affecting the Emax) and diabetic (increased
the EC50 value and inhibited the Emax) rabbits. These results
confirm that the contraction of the rabbit carotid artery in
response to endothelin-1 is mediated by endothelin ETA
receptors, as has been previously reported in the rabbit
carotid artery (White et al., 1993; Calo et al., 1996). BQ-
123 inhibited the maximal contraction elicited by endothe-
lin-1 in carotid arteries from diabetic rabbits but not in
control rabbits, suggesting a greater participation of endo-
thelin ETA receptors in diabetes, which could partially
contribute to the hyperreactivity of the rabbit carotid artery
to endothelin-1 in diabetes. This would be in accordance
with a recent study that shows an enhanced activity of
endogenous endothelin-1 on endothelin ETA receptors in
the resistance vessels of patients with type II diabetes
(Cardillo et al., 2002). In arteries from control rabbits, the
incubation of unrubbed arterial segments with BQ-788
significantly enhanced the contraction in response to endo-
thelin-1, thus suggesting the existence of endothelial endo-
thelin ETB receptors mediating vasodilatation. There is
controversy about the presence of endothelin ETB receptors
in the rabbit carotid artery. Several studies have failed to
find endothelin ETB receptors in this artery (White et al.,
1993; Lodge et al., 1995; Calo et al., 1996). Because
endothelin ETB activation mediates opposite effects
depending of the endothelial or muscular location of the
receptor, the sum of these effects could have masked the
effect of the activation of each of them individually.
However, other studies describe the presence of endothelin
ETB receptors functionally active in the rabbit carotid
artery, and their possible role in several pathophysiological
conditions (Lauth et al., 2000; Cattaruzza et al., 2002). In
vivo studies have demonstrated that endothelin-1 contrib-
utes to regulation of the vascular tone of human resistancevessels by stimulating NO activity, and this effect is
mediated through endothelial endothelin ETB receptors
(Cardillo et al., 2000). In arteries from diabetic rabbits,
BQ-788 displaced to the right the concentration–response
curve of endothelin-1 in unrubbed arteries, thus indicating
that vasodilatation mediated by endothelial endothelin ETB
receptors is impaired in diabetes. Therefore, the impairment
of the modulatory activity of NO on the response to
endothelin-1 of the carotid artery isolated from diabetic
rabbits observed in the present study could be the conse-
quence of a reduction of the number or the activity of
endothelial endothelin ETB receptors. It has been recently
reported that endothelin ETB receptor-mediated release of
NO is reduced in renal perfusates in experimental models of
hypertension, diabetes mellitus, and hypercholesterolemia
(Kakoki et al., 1999). The incubation of rubbed arteries with
the antagonist of endothelin ETB receptors, BQ-788, sig-
nificantly displaced to the right the concentration–response
curve with respect to the curve obtained in untreated rubbed
arteries, both in control and diabetic rabbits, thus indicating
the existence of endothelin ETB receptors located in smooth
muscle cells that mediate vasoconstriction. Moreover, the
maximal contraction in response to endothelin-1 obtained in
BQ-788-treated rubbed arteries from diabetic rabbits was
significantly greater than that obtained in BQ-788-treated
rubbed arteries from control rabbits, thus supporting the
above-mentioned hypothesis that the hyperreactivity of
carotid artery to endothelin-1 could be associated with an
increase either in the number or in the activity of endothelin
ETA receptors.
In summary, experimental diabetes induces hyperreactiv-
ity of the rabbit carotid artery to endothelin-1 by a mech-
anism that at least includes: (1) enhanced activity of
muscular endothelin ETA receptors; (2) impairment of
endothelin ETB receptor-mediated NO release; and (3)
enhancement of the production of thromboxane A2. This
hyperreactivity may contribute to the increased risk of
cerebrovascular disease in diabetic patients and drugs tar-
geting the endothelin-1 system might prevent cerebrovas-
cular complications in these patients.Acknowledgements
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